Skip to main content
Equibles
NKTR logo

NKTR · Nektar Therapeutics

Track NKTR — free

Use NKTR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NKTR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$74.02 -0.51 (-0.68%) At close · Aug 21
Market Cap
$2.53B
Shares
34.14M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$74.02 Open$75.10 Day$72.83–76.23 52W close$27.03–100.35 Avg vol 30d669K Short int6.3M · 18.5% float · 8.6d Short vol56% Last earningsAug 13, 2026 DataJun 2025–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Jun 9, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 16, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 15.1 · calm Equity put/call 0.51
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +16%
      above
      Price vs 50-day avg +7%
      above
      RSI (14) 54
      neutral
      MACD trend Negative
      52-week position 64%
      mid-range
      Momentum
      relative strength
      Strong
      1-month return +5%
      trailing
      6-month return +8%
      trailing
      YTD return +75%
      this year
      Relative strength −3%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $69 › 200d $64 — 50d above 200d
      Institutional flow Accumulating
      +11% holders QoQ · +72 funds added
      Insider flow Distributing
      Net -$43.5K over 90 days · 100% sells
      Short interest Falling
      18.46% of float · ▼ -7.6% MoM · 8.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      243 holders — near 3-yr high, broad support
      Squeeze score 78
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth +86%
      Y/Y
      EPS growth −12%
      Y/Y
      Free cash flow $-208.7M
      Balance sheet $15.1M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 89%
      annualized · 1-yr
      Max drawdown −47%
      past year
      ATR 4.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the Earnings Call filed Sep 30, 2023
      full-year
      GAAP R&D operating expenses GAAP $105M – $115M
      Full-year non-cash interest expense $20M – $25M
      end of this year
      Cash and investments at least $320M
      Prior guidance period ended · from the Earnings Call filed Mar 31, 2024
      Cash and investments · end of 2024 $200M – $225M
      Revenue · full year 2024 $75M – $85M
      Product sales · full year 2024 $20M – $25M
      R&D expense · full year 2024 $120M – $130M
      Noncash royalties · full year 2024 $55M – $65M
      G&A expense · full year 2024 $70M – $75M
      Noncash interest expense · full year 2024 $20M – $25M
      Cash · end of 2024 $200M – $225M
      Guided vs delivered · last 2 settled
      Revenue full year of 2024
      guided $75M – $85M
      $98.43M Beat +23.0%
      GAAP revenue full year 2023
      guided $80M – $90M
      $90.12M Beat +6.0%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +16% Bullish
      Price vs 50-day avg
      +7% Bullish
      RSI (14)
      54 Neutral
      MACD trend
      Negative Bearish
      52-week position
      64% Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $69 › 200d $64 — 50d above 200d
      Institutional flow Accumulating
      +11% holders QoQ · +72 funds added
      Insider flow Distributing
      Net -$43.5K over 90 days · 100% sells
      Short interest Falling
      18.46% of float · ▼ -7.6% MoM · 8.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      243 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $27 Now $74 · 64% Range high $100
      vs 200-day avg +16% vs 50-day avg +7%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NKTR
      Nektar Therapeutics
      this stock
      		$2.53B +75.1% +86.0% — 18.5%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.91B +20.9% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $85.87B +8.1% +20.8% 20.7 3.3%
      ARGX
      Argenx SE
      		 $64.66B +23.6% — — 2.1%
      CSLLY
      Csl Ltd
      		 $57.97B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      243
      % held
      111.4%
      Net QoQ
      +9.9M sh
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      101
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      6.3M
      Days to cover
      8.6d
      Change
      -516.5K sh
      View
      Short Volume
      Short vol %
      56%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      10
      Value
      $693
      As of
      Jul 23, 2026
      View
      Off-Exchange
      Off-exchange %
      45.1%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$43.5K
      Buyers / Sellers
      0 / 2
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $55.2M
      Net income (FY)
      $-164.1M
      EPS diluted
      $-9.73
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 14, 2026
      This year
      17
      View
      Proposed Sales
      Value
      $13.4K
      Shares
      186
      Filed
      Aug 18, 2026
      View
      Exempt Offerings
      Offering
      $30.0M
      Filed
      Mar 19, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Jun 9, 2025; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      NKTR +1.4% +4.7% +8.3% +4.7% +75.1%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +2.7% +1.0% -3.3% +2.2% +62.8%
      Key facts CIK 906709 CUSIP 640268306 13F (30d) 246 filings 231 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)